CME: Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
CDI experts discuss the changes to the IDSA and SHEA guidelines, the roles of therapies, and the importance of an interprofessional team approach.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Clostridium difficile infection (CDI) is the leading cause of infectious nosocomial diarrhea in developed countries. Approximately 25% of patients treated for this opportunistic infection experience recurrent or recalcitrant disease, and up to 40% of those patients develop an additional recurrence. This alarming trend has sparked a much-needed update in management guidelines that aim to reduce the risk of recurrence and enhance patient care. 

    This activity will discuss changes to the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines, the roles of antibiotic and non-antibiotic therapies, and the importance of an interprofessional team approach to CDI.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Erik R. Dubberke, MD, MSPH
    Associate Professor of Medicine
    Clinical Director, Transplant Infectious Diseases
    Washington University School of Medicine
    Saint Louis, MO

    Dr. Dubberke receives consulting fees from Merck, Rebiotix, Summit, and Synthetic Biologics; and has contracted research for Pfizer.


    Kevin Garey, PharmD, MS
    Professor and Chair
    University of Houston College of Pharmacy
    Dept of Pharmacy Practice and Translational Research
    Houston, TX

    Dr. Garey receives consulting fees from Merck, Summit PLC, and Seres Therapeutics.


    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration between the members of the professional teams who care for patients with CDI.  After participating in this educational activity, participants should be better able to:

    • Summarize the changing epidemiology and demographics of patients at risk for CDI recurrence.
    • More knowledgeably select therapeutic regimens for patients at high risk for recurrent CDI, including validated non-antibiotic agents.
    • Analyze the impact of the recent changes made to the Infectious Diseases Society of America guidelines on CDI diagnosis accuracy and patient outcomes.
  • Target Audience

    This activity is designed to meet the educational needs of the members of the professional teams who care for patients with infectious disease, including infectious disease specialists, primary care physicians, registered nurses, nurse practitioners, physician assistants, and pharmacists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Prova Education newsletters.

Better education for a better you.

* Required

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free